ALK and non-small cell lung carcinoma: The identification of molecular subtypes of non-small cell lung carcinoma (NSCLC) has transformed the clinical management of this disease, which is best exemplified by the clinical success of targeting the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKI) as the first line of treatment [2].